The provided UK guideline excerpts do not contain specific recommendations for the follow-up care of patients treated for anal cancer to monitor for recurrence NICE NG151,NICE NG83,NICE NG122,NICE NG14.
While one guideline details follow-up for non-metastatic colorectal cancer, including serum carcinoembryonic antigen (CEA) and CT scans of the chest, abdomen, and pelvis for the first 3 years after potentially curative surgical treatment, this guidance is specific to colorectal cancer and not anal cancer NICE NG151. Other guidelines provided cover oesophago-gastric cancer, lung cancer, and melanoma, none of which are relevant to anal cancer follow-up NICE NG83,NICE NG122,NICE NG14.